Merck/Schering Zetia (Ezetimibe) Will Be Supported By Three Sales Forces
Executive Summary
Merck will follow the Zocor model in launching Zetia (ezetimibe) into the cholesterol-lowering class by relying on separate sales forces and a co-promotion partner to establish the new product
You may also be interested in...
Schering/Merck Zetia Clears FDA; Price Favors Combo With Low-Dose Zocor
Merck and Schering-Plough are pricing Zetia so that combination use with Zocor 10 mg is attractive compared to high-dose Zocor monotherapy
Schering/Merck Zetia Clears FDA; Price Favors Combo With Low-Dose Zocor
Merck and Schering-Plough are pricing Zetia so that combination use with Zocor 10 mg is attractive compared to high-dose Zocor monotherapy
Schering-Plough Zetia Could Be More Important Growth Product Than Claritin
Schering-Plough's cholesterol agent Zetia could be an even larger growth driver than Claritin, CEO Richard Kogan told analysts at the company's annual meeting on July 16